Report of the second joint meeting of ESOT and AST: current pipelines in biotech and pharma (Q44911053)

7 December 2017

Report of the second joint meeting of ESOT and AST: current pipelines in biotech and pharma (English)

1 reference

7 December 2017

Teun van Gelder

1

1 reference

7 December 2017

Carla Baan

series ordinal

2

1 reference

7 December 2017

Flavio Vincenti

series ordinal

3

1 reference

7 December 2017

Roslyn B Mannon

series ordinal

4

1 reference

7 December 2017

4 July 2013

1 reference

7 December 2017

Transplant International

1 reference

7 December 2017

26

1 reference

7 December 2017

9

1 reference

7 December 2017

938-948

1 reference

Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells

7 December 2017

1 reference

Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.

21 January 2018

1 reference

Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study

21 January 2018

1 reference

Costimulatory pathways in transplantation

21 January 2018

1 reference

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

21 January 2018

1 reference

Antigen-specific induced Foxp3+ regulatory T cells are generated following CD40/CD154 blockade

21 January 2018

1 reference

A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects

21 January 2018

1 reference

Targeting B cells and antibody in transplantation

21 January 2018

1 reference

B lymphocytes differentially influence acute and chronic allograft rejection in mice

21 January 2018

1 reference

BAFF and BAFF-R levels are associated with risk of long-term kidney graft dysfunction and development of donor-specific antibodies

21 January 2018

1 reference

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation.

21 January 2018

1 reference

The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review.

21 January 2018

1 reference

Calcineurin inhibitors: short-term friend, long-term foe?

21 January 2018

1 reference

Chronic calcineurin inhibitor nephrotoxicity-lest we forget

21 January 2018

1 reference

Optimal immunosuppression to prevent chronic allograft dysfunction

21 January 2018

1 reference

Monitoring tolerance and rejection in organ transplant recipients.

21 January 2018

1 reference

Peripheral biomarkers for individualizing immunosuppression in transplantation--regulatory T cells

21 January 2018

1 reference

Diannexin protects against renal ischemia reperfusion injury and targets phosphatidylserines in ischemic tissue

21 January 2018

1 reference

Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement

21 January 2018

1 reference

Real and artificial immune systems: computing the state of the body.

21 January 2018

1 reference

Chronic rejection of a lung transplant is characterized by a profile of specific autoantibodies

21 January 2018

1 reference

Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial

21 January 2018

1 reference

The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation.

21 January 2018

1 reference

Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients.

21 January 2018

1 reference

Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients.

21 January 2018

1 reference

The search for CNI-free immunosuppression: no free lunch.

21 January 2018

1 reference

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

21 January 2018

1 reference

Tofacitinib for the treatment of rheumatoid arthritis

21 January 2018

1 reference

Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics

21 January 2018

1 reference

Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients

21 January 2018

1 reference

Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.

21 January 2018

1 reference

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

21 January 2018

1 reference

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

21 January 2018

1 reference

Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression

21 January 2018

1 reference

Anti-complement component C5 mAb synergizes with CTLA4Ig to inhibit alloreactive T cells and prolong cardiac allograft survival in mice.

21 January 2018

1 reference

The optimal chain length for kidney paired exchanges: an analysis of the Dutch program.

21 January 2018

1 reference

Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocols

21 January 2018

1 reference

Significance of the positive crossmatch test in kidney transplantation

21 January 2018

1 reference

Clinical relevance of circulating donor-specific HLA antibodies

21 January 2018

1 reference

Detection and clinical relevance of donor specific HLA antibodies: a matter of debate

21 January 2018

1 reference

Mature wines are better: CDC as the leading method to define highly sensitized patients

21 January 2018

1 reference

Late kidney allograft loss: what we know about it, and what we can do about it

21 January 2018

1 reference

Therapeutic targets in the treatment of allograft fibrosis

21 January 2018

1 reference

Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies

21 January 2018

1 reference

Molecular and structural consequences of early renal allograft injury

21 January 2018

1 reference

HMGB1 contributes to kidney ischemia reperfusion injury

21 January 2018

1 reference

Nontransgenic Hyperexpression of a Complement Regulator in Donor Kidney Modulates Transplant Ischemia/Reperfusion Damage, Acute Rejection, and Chronic Nephropathy

21 January 2018

1 reference

siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury

21 January 2018

1 reference

Pirfenidone for diabetic nephropathy

21 January 2018

1 reference

Decorin modulates collagen matrix assembly and mineralization

21 January 2018

1 reference

Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients

21 January 2018

1 reference

Deleterious effect of CTLA4-Ig on a Treg-dependent transplant model

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/TRI.12140

1 reference

7 December 2017

1 reference